IL33 and neoplasm: A similar observation was recently reported in the CT26 adenocarcinoma model, where rIL-33 administration to tumor-bearing mice promoted, while IL-33 blockade reduced, the expansion of ST2+ Treg cells in tumor tissue and spleen (43).